The Company’s business journey began in 2003 through the business expansion of Dirgantara Yudha Artha (DYA Group) into the medical device sector under PT Oneject Indonesia. Since then, the Company has strengthened its role in the national healthcare sector through various business line developments and strategic partnerships.

Ekspansi Regional

In 2004, the Company began its role in the procurement of Auto Disable Syringes (ADS) and Safety Boxes by establishing long-term partnerships with the Ministry of Health, Health Offices, and Community Health Centers (Puskesmas) across Indonesia.

Sertifikasi & Standar Mutu

Entering 2010, the Company expanded its distribution by providing Blood Screening Reagents to the Indonesian Red Cross (PMI) and Hospital Blood Transfusion Units (UTD RS) across Indonesia as part of its support for the national blood service system.

Proyek Skala Besar Pertama

In 2013, the Company supported government programs through the distribution of Contraceptive Devices and Drugs (ALOKON) to the National Population and Family Planning Board (BKKBN), strengthening its contribution to public health programs.

Penghargaan Industri

Business development continued in 2016 with the procurement of Apheresis Kits distributed to PMI, public and private hospitals, stem cell clinics, and UTD RS to support transfusion services and medical therapies.

Hari Ini

In March 2017, the transfer of medical device distribution business activities occurred from PT Dirgantara Yudha Artha to PT Itama Ranoraya as part of the restructuring and strengthening of the Company's business structure.

Hari Ini

In 2019, PT Itama Ranoraya Tbk was officially listed as a public company on the Indonesia Stock Exchange with the stock code “IRRA”.

Hari Ini

In 2020, the Company diversified its business into the pharmaceutical sector through the launch of Avimac products as one of the initial steps for a wider healthcare business line expansion.

Hari Ini

The year 2022 became a business transformation phase with expansion into the surgical sector, the addition of eight new strategic partners, and the strengthening of the “Hi-Tech Healthcare Solutions” portfolio. During this period, the Company also updated its identity as part of the corporate transformation.

Hari Ini

Business expansion continued in 2023 with the Company’s entry into the distribution of radiotherapy and hemodialysis (HD) machines, as well as expansion into the wholesale trade of fertilizers, agrochemical products, veterinary medical devices, radioactive substances, and ionizing radiation generators.

Hari Ini

In 2024, the Company expanded its portfolio into the critical care sector through a strategic partnership with an international partner from the United States.

Hari Ini

In 2025, the Company expanded its business portfolio into the orthopedic sector through strategic cooperation with a partner from South Korea, as well as becoming a distributor of tuberculin products to support the needs of State-Owned Enterprise (BUMN) partners.